Reuters logo
Oxford BioMedica pauses some trials after finding potential impurities
June 3, 2013 / 6:41 AM / in 4 years

Oxford BioMedica pauses some trials after finding potential impurities

(Reuters) - Gene-based biopharmaceutical company Oxford BioMedica said it put some of its trials on hold, after the company detected very low concentrations of potential impurities in a raw material.

Oxford Biomedica said it paused recruitment for its RetinoStat phase I, StarGen phase I/IIa and UshStat phase I/IIa studies.

“No safety concerns relating to any of the aforementioned products have been identified in any pre-clinical and clinical data generated to date and there is no reason to believe that the favorable safety profile of these products will be affected,” the company said in a statement.

Oxford BioMedica added that it was working closely with regulatory authorities to complete its investigations.

Reporting by Brenton Cordeiro in Bangalore; Editing by Supriya Kurane

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below